ChovÃ-Trull, M.; MegÃas-Vericat, J.E.; Bonanad-Boix, S.; Haya-Guaita, S.; Cid-Haro, A.R.; Aguilar-Rodriguez, M.; Palanques-Pastor, T.; Garcia-Pellicer, J.; Poveda-Andrés, J.L.
Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients. Hematol. Rep. 2025, 17, 53.
https://doi.org/10.3390/hematolrep17050053
AMA Style
ChovÃ-Trull M, MegÃas-Vericat JE, Bonanad-Boix S, Haya-Guaita S, Cid-Haro AR, Aguilar-Rodriguez M, Palanques-Pastor T, Garcia-Pellicer J, Poveda-Andrés JL.
Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients. Hematology Reports. 2025; 17(5):53.
https://doi.org/10.3390/hematolrep17050053
Chicago/Turabian Style
ChovÃ-Trull, Maria, Juan Eduardo MegÃas-Vericat, Santiago Bonanad-Boix, Saturnino Haya-Guaita, Ana Rosa Cid-Haro, Marta Aguilar-Rodriguez, Tomás Palanques-Pastor, Javier Garcia-Pellicer, and Jose Luis Poveda-Andrés.
2025. "Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients" Hematology Reports 17, no. 5: 53.
https://doi.org/10.3390/hematolrep17050053
APA Style
ChovÃ-Trull, M., MegÃas-Vericat, J. E., Bonanad-Boix, S., Haya-Guaita, S., Cid-Haro, A. R., Aguilar-Rodriguez, M., Palanques-Pastor, T., Garcia-Pellicer, J., & Poveda-Andrés, J. L.
(2025). Real-World Assessment of Pharmacokinetics, Clinical Outcomes, and Costs After Switching from Standard Half-Life to Extended Half-Life FVIII in Well-Controlled Hemophilia A Patients. Hematology Reports, 17(5), 53.
https://doi.org/10.3390/hematolrep17050053
